EMA Authorised: SomaKit TOC (edotreotide) — Novartis Europharm Limited

View source ↗

Summary

EMA authorised SomaKit TOC (edotreotide) for neuroendocrine tumors and radionuclide imaging; orphan medicine status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• SomaKit TOC (edotreotide)

Snippet

Status: Authorised. Therapeutic area: Neuroendocrine Tumors;Radionuclide Imaging. MAH: Novartis Europharm Limited. Decision date: 27/08/2026. Orphan medicine